A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
The purpose of this study was to assess the safety and tolerability of ABBV-951 (Foslevodopa/Foscarbidopa) in participants with Parkinson's disease (PD).
This was a single-arm study with preplanned analyses conducted by dose subgroup (Low Dose or High Dose) based on the modal total daily dose (most frequent dose) over the treatment period.
Inclusion Criteria:
Exclusion Criteria:
Fountain Valley, California 92708, United States
Boca Raton, Florida 33486, United States
Chicago, Illinois 60611-2927, United States
Raleigh, North Carolina 27612, United States
Greenville, South Carolina 29605-4255, United States
Copenhagen NV, Capital Region 2400, Denmark
Asahikawa-shi, Hokkaido 070-8644, Japan
Suita-shi, Osaka 565-0871, Japan
Bunkyo-ku, Tokyo 113-8431, Japan
Kodaira-shi, Tokyo 187-8551, Japan
Saint Petersburg, Sankt-Peterburg 197101, Russia